MedTrace Logo

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

NCT02863991 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2024-07-03

Study results available
· View outcomes & findings →

Summary

This was a Phase 1/2 open-label study of ONC201 administered orally once every week in combination with dexamethasone in adults with relapsed/refractory multiple myeloma. The primary objective of this study was to evaluate the antitumor efficacy of ONC201.

Note: This study was completed by predecessor company, Oncoceutics, Inc.

Conditions

Interventions

DRUG

ONC201

375 mg or 625 mg ONC201

DRUG

Dexamethasone

20 mg dexamethasone

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-19
Primary Completion
2019-09-17
Completion
2019-12-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02863991 on ClinicalTrials.gov